Cypionate
Facts

The record behind the words

Read the source.

Start with the exact document. Access dates show when we checked a page; its own revision date tells you which record it contains. Official clinical and regulatory records are linked. Provider records are identified for attribution without a purchasing link.

Provider product page

CoreAge Rx: Injectable Testosterone Cypionate

Accessed 2026-09-27. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Regulatory explanation

FDA: Understanding the Risks of Compounded Drugs ↗

Accessed 2026-09-27. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Regulatory explanation

FDA: Generic Drugs Questions and Answers ↗

Accessed 2026-09-27. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Exact product labeling

Pfizer: Depo-Testosterone prescribing information, revised September 2025 ↗

Accessed 2026-09-27. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Current professional society statement

Endocrine Society: Statement on Testosterone Replacement Therapy, July 16, 2026 ↗

Accessed 2026-09-27. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Clinical practice guideline

Endocrine Society: Testosterone Therapy in Men With Hypogonadism guideline, 2018 ↗

Accessed 2026-09-27. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Current regulatory information

FDA: Testosterone Information and June 2026 labeling requests ↗

Accessed 2026-09-27. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Provider product and price description

TRT Nation: Separate 2026 Frequently Asked Questions

Accessed 2026-09-27. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Provider cost information

TRT Nation: Cost and Process, updated April 2026

Accessed 2026-09-27. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Provider pharmacy and service information

TRT Nation: Main Frequently Asked Questions

Accessed 2026-09-27. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Provider product page

Hone Health: Testosterone Cypionate Injections

Accessed 2026-09-27. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Provider medication and membership pricing

Hone Health: Plus Membership for Men

Accessed 2026-09-27. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Provider membership terms

Hone Health: Basic, Plus and Premium Membership Overview

Accessed 2026-09-27. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Exact product structured labeling

DailyMed: Depo-Testosterone record updated August 21, 2026; internal label revision September 2025 ↗

Accessed 2026-09-27. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Regulatory medication-error explanation

FDA: Differences in strength expression on injectable product labels; updated May 21, 2024 ↗

Accessed 2026-09-27. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Regulatory patient information

FDA: Understanding Unapproved Use of Approved Drugs Off Label ↗

Accessed 2026-09-27. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Exact product structured labeling

DailyMed: Xyosted testosterone enanthate injection prescribing information ↗

Accessed 2026-09-27. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Regulatory ingredient and database definitions

FDA: Inactive Ingredients in Approved Drug Products Search, Frequently Asked Questions ↗

Accessed 2026-09-27. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Historical regulatory announcement

FDA: Class-wide testosterone labeling changes, February 28, 2025 ↗

Accessed 2026-09-27. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official departmental urology scope explicitly including hypogonadism; not an individual medicine or product list.

NYU Langone: Department of Urology Divisions

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official clinician account of testosterone-deficiency care; reproductive-endocrinology collaboration is specifically fertility related.

NYU Langone: Hossein Sadeghi-Nejad, MD

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official Iris Cantor clinical-service list including hypogonadal conditions; center-specific scope, not a system-wide formulary.

NewYork-Presbyterian: Iris Cantor Men’s Health Center clinical services

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official condition information concerning hypogonadism, possible causes and conditional investigations; not a product-specific label or universal testing plan.

Hartford HealthCare: Tallwood hypogonadism

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official Tallwood endocrine-service description and condition context; not an individual medicine selection or complete formulation record.

Hartford HealthCare: Tallwood Men’s Health endocrinology

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official low-testosterone testing and treatment service with broad treatment categories; no exact preparation or individual instructions inferred.

Henry Ford Health: Men’s Health Center low testosterone

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official endocrine service including male hypogonadism; general clinical coordination does not identify an individual preparation.

Corewell Health: Endocrinology

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official named adult endocrinologist biography including hypogonadism; not a system-wide medicine list or protocol.

Geisinger: Vishaal Gupta, MD

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official clinical profile explicitly including evaluation and treatment of low testosterone; fertility team work remains separately scoped.

UCSF: James F. Smith clinical profile

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official general hypogonadism patient information; clinical findings and treatment categories do not identify an individual medicine.

UCSF Urology: Hypogonadism (Low Testosterone)

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official general urology service and professional-role overview; not a low-testosterone-specific product or pharmacy record.

Yale Medicine: Urology

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official sexual and reproductive medicine clinician biography including low-testosterone treatment; bibliography and fertility work are not product identity or outcome evidence.

Yale Medicine: Stanton Honig, MD

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official adult urology and second-opinion service including low-testosterone concerns; personal access and exact medicine decisions are not established.

RUSH: Urology Services

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

March 2018 official guideline summary on diagnosis, cause evaluation, clinical limitations and reassessment; not individualized instructions or a product label.

Endocrine Society: Testosterone Therapy for Hypogonadism Guideline Resources ↗

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

July 16, 2026 professional statement emphasizing accurate diagnosis and unresolved long-term safety; not a product-specific approval or institution-specific outcome.

Endocrine Society: Statement on Testosterone Replacement Therapy, July 16, 2026 ↗

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official FDA class information describing associated medical-condition context, AndroGel-specific TRAVERSE evidence and requested June 2026 label changes; not proof of every product label’s implementation.

FDA: Testosterone Information ↗

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official FDA explanation of approved-generic requirements, reference products and permitted differences; no approval or equivalence inference for an unidentified preparation.

Generic Drugs: Questions & Answers ↗

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official FDA label-expression discussion, updated May 21, 2024 to reference final May 2022 guidance; historical cases involve other medicines, not reviewed institutions or cypionate.

Differences in strength expression on product labels of compounders and conventional manufacturers may lead to dosing errors ↗

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official FDA distinction between an approved drug and unapproved uses; no patient-specific treatment or preparation-approval inference.

Understanding Unapproved Use of Approved Drugs "Off Label" ↗

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official FDA explanation of inactive ingredients in approved finished products, route/form context and database limits; not an individual ingredient or exposure assessment.

Inactive Ingredients in Approved Drug Products Search: Frequently Asked Questions ↗

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official clinical program including low testosterone; team and condition descriptions do not identify an individual prescription, preparation, manufacturer or medicine contents.

UPMC: Men’s Health Center

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Professional statement dated July 16, 2026; accurate diagnosis, multiple symptom contributors and continuing long-term uncertainty remain separate from medicine identity and individual eligibility.

Endocrine Society: Statement on Testosterone Replacement Therapy (July 16, 2026) ↗

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

FDA explanation of approved generic-drug standards, reference products, bioequivalence and allowable differences. No approval or equivalence is inferred for an uninspected preparation; inactive-ingredient differences do not predict personal tolerability.

FDA: Generic Drugs — Questions & Answers ↗

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

FDA database FAQ for ingredients in approved finished products, with route and dosage-form context. Database presence or a substance identifier does not establish the contents, approval, stability or personal suitability of an unseen preparation; no exposure calculations are used.

FDA: Inactive Ingredients in Approved Drug Products — FAQ ↗

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

FDA explanatory article updated May 21, 2024, distinguishing final 2022 guidance from terminology in the older 2018 discussion. Examples involve other medicines, not these institutions or cypionate; no calculations or administration instructions are supplied.

FDA: Differences in strength expression on compounder and manufacturer labels ↗

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official low-testosterone clinical assessment and conditional treatment-category account; no individual diagnosis, cypionate preparation or route is established. Broad benefit and age-related language is not adopted as a personal outcome or eligibility rule.

UC San Diego Health: Low Testosterone

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official men’s-health service; its multidisciplinary collaboration and andrology laboratory are described within fertility care, not proof of a universal hormone pathway or medicine identity.

UC San Diego Health: Men’s Reproductive and Sexual Health

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

2018 professional guideline resource and recommendation summary; clinical diagnosis, cause and fertility context, not an institution-specific protocol or personal treatment instruction.

Endocrine Society: Testosterone Therapy for Hypogonadism Guideline Resources (2018) ↗

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

FDA patient explanation of an approved drug used outside approved labeling. Clinical consideration does not establish FDA approval of that use or confer approval on a compounded preparation; no individual use or route is selected.

FDA: Understanding Unapproved Use of Approved Drugs ↗

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official urologic service covering several distinct conditions; injection descriptions retain their own clinical subjects and do not identify an individual testosterone product.

UCI Health: Sexual Dysfunction Services

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official men’s-health and andrology service; the broad treatment lists and pellet reference do not establish cypionate formulation, pharmacy or individual prescribing.

UCI Health: Men’s Health Services

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official testosterone-deficiency service and broad treatment overview. General administration summaries, numerical schedules and diagnostic timing are not reproduced as product-specific or personal instructions.

UC Davis Health: Testosterone Deficiency

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official urology specialty account including hormone-related male infertility; service scope does not establish an individual treatment or preparation.

UC Davis Health: Urology Specialties

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Current FDA class overview describing June 2026 requested labeling changes; not proof of implementation in every exact product document. TRAVERSE discussion concerns the named AndroGel preparation, not an unidentified cypionate product.

FDA: Testosterone Information ↗

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official fertility and men’s sexual-health clinical service. Different procedure descriptions retain their clinical subjects; broad effectiveness and safety language is not evidence of an individual outcome or exact formulation.

Keck Medicine of USC: Fertility and Men’s Sexual Health Center

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official men’s-health service with cause-focused hypogonadism care and hormone expertise; professional capability does not identify a selected preparation, product inventory or individual suitability.

OHSU: Men’s Health and Fertility

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official men’s-health service describing low-testosterone assessment and discussion of treatment risks and benefits; clinical discussion does not establish product approval, exact formulation or personal prescribing.

UW Medicine: Men’s Health

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official male-hypogonadism clinical service; the condition-specific role does not identify an individual medicine or preparation.

Vanderbilt Health: Male Hypogonadism

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official endocrine service covering several hormone and metabolic concerns. Broad treatment-family language is not an exact testosterone product record or proof of a shared individual pathway.

Vanderbilt Health: Endocrinology, Diabetes and Metabolism

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official low-testosterone clinical account with several treatment forms; general forms do not establish identical preparations, an individual route or an exact product label.

Emory Healthcare: Low Testosterone

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official testosterone-treatment service describing clinical testing and monitoring. These statements are not a personal schedule, a product-quality finding or proof of formulation identity.

Emory Healthcare: Low Testosterone Treatments

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official clinical program, internally reviewed January 24, 2025. Explicit central hypogonadism and integrated endocrine care; not evidence that an individual has pituitary disease or needs every listed investigation.

Duke Health — Pituitary Disorders

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official adult endocrinologist profile explicitly including hypogonadism. A documented clinical scope, without ratings, outcome claims or verified personal access.

Duke Health — Adrienne Barnosky, DO

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official clinical program discussion of male hypogonadism, underlying causes, second opinions and referring-clinician coordination. Telemedicine is qualified by appropriateness; no universal remote access or confirmed treatment.

Duke Health — Duke Pituitary Program Expands Expertise With New Physician Leadership

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official assessment and follow-up service describing symptom history, medicine and health history, examination and possible tests. Northeast Ohio and Florida locations. The page does not establish a complete medicine list or an individual treatment.

Cleveland Clinic — Get Low Testosterone Treatment

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official condition-specific care directory, dated September 20, 2025. Endocrinology and pituitary-gonad-adrenal specialty group plus a displayed Rochester clinician. Does not establish identical access at every campus.

Mayo Clinic — Male hypogonadism: Doctors and departments

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official Rochester, Minnesota men’s health program, dated October 31, 2024. Clinical breadth and research activity are not individual outcomes or comparative performance. The separate condition directory confirms specific hypogonadism care.

Mayo Clinic — Men’s Health overview

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official urologist profile explicitly treating low testosterone and directing Male Infertility and Men’s Health. Background practice locations and detailed Lutherville location remain distinct. Availability badges, ratings and insurance lists are not personal access confirmation.

Johns Hopkins Medicine — Amin Herati, MD

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official endocrinology service diagnosing and treating hypogonadism, investigating causes and collaborating on infertility. Timing instructions, personal diagnostic rules and claimed research benefits are not reproduced as advice.

Mount Sinai — Male Hormone Disorders

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official condition-and-care record explicitly describing a reproductive urologist’s history, examination and cause assessment. The concise page does not establish a named formulation, supplied medicine or detailed follow-up schedule.

Northwestern Medicine — Hypogonadism

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official low-testosterone clinical service within a wider reproductive and men’s health program. Santa Monica and video descriptions do not establish unrestricted access. Listed forms and collaboration do not confirm a selected prescription or completed consultation.

UCLA Health — The Men’s Clinic at UCLA

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official clinic condition page used for blood-assessment context. Broad response timelines, minimal-adverse-effect assurances, administration instructions and fixed monitoring intervals are not adopted; independent current guidance qualifies the assessment discussion.

UCLA Health — Low Testosterone

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official diagnosis outline covering symptoms, examination and hormone testing, linked to actual endocrine, urology and male reproductive services. No individual testing algorithm, universal clinic access or specified product inferred.

Stanford Health Care — Hypogonadism diagnosis

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official clinical assessment, follow-up and fertility discussion. Questionnaire reference is not a diagnosis or eligibility rule. Older general reassurance and references are qualified by current independent guidance; no technique, dosage, response guarantee or acquisition instructions reproduced.

University of Utah Health — Hypogonadism

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Professional guideline resources dated March 19, 2018, providing a recommendations summary. Covers diagnosis, cause evaluation, fertility cautions and clinical monitoring principles; no personal thresholds, dose or testing calendar.

Endocrine Society — Testosterone Therapy for Hypogonadism Guideline Resources ↗

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Current professional statement on accurate diagnosis, reversible contributors, limits of asymptomatic screening, testing quality and unresolved long-term safety. No numerical cutoff, regimen or personal treatment decision reproduced.

Endocrine Society — Statement on Testosterone Replacement Therapy, July 16, 2026 ↗

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official regulatory overview reporting June 2026 requested labeling updates and AndroGel-specific TRAVERSE context. A request does not prove implementation in each product document; findings are not reassigned to unidentified injectable products or presented as blanket safety clearance.

U.S. Food and Drug Administration — Testosterone Information ↗

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official FDA explanation of approved generic requirements and permitted differences, including inactive ingredients. It does not establish the identity, approval or suitability of an unnamed preparation.

FDA — Generic Drugs: Questions & Answers ↗

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official FDA strength-labeling notice, updated May 21, 2024 with a final-guidance reference. Concentration and total container strength are different expressions; examples involving other medicines are not evidence of testosterone errors or institutional practice. No calculations or personal quantities provided.

FDA — Differences in strength expression on product labels ↗

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official FDA explanation of unapproved uses of approved medicines. Approval of a product is distinct from evidence for a particular use; no individualized use or route is recommended.

FDA — Understanding Unapproved Use of Approved Drugs ↗

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Official FDA FAQ about ingredients in approved finished medicines, with route and dosage-form context. A database entry does not identify the contents or approval status of an unnamed preparation.

FDA — Inactive Ingredients in Approved Drug Products FAQ ↗

Accessed 2026-09-29. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Primary clinical or regulatory guidance

FDA: class-wide testosterone labeling changes (checked October 13, 2026) ↗

Accessed 2026-10-13. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Primary clinical or regulatory guidance

FDA: risks of compounded medicines (checked October 13, 2026) ↗

Accessed 2026-10-13. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Provider public service document

Enhanced: testosterone injections and get-started offer (checked October 13, 2026)

Accessed 2026-10-13. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Primary clinical or regulatory guidance

Endocrine Society: testosterone therapy guideline (checked October 13, 2026) ↗

Accessed 2026-10-13. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Provider public service document

Enhanced: TRT supply offers and compounded cypionate (checked October 13, 2026)

Accessed 2026-10-13. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Provider public service document

Lowcountry Male: clinic services and cypionate listing (checked October 13, 2026)

Accessed 2026-10-13. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Provider public service document

Lowcountry Male: plans, consultation and insurance conditions (checked October 13, 2026)

Accessed 2026-10-13. Provider claims describe public advertising, not independently observed treatment.

Articles using this source

Provider public service document

Enhanced: terms of service (checked October 13, 2026)

Accessed 2026-10-13. Provider claims describe public advertising, not independently observed treatment.

Articles using this source